Sign Up for Free!

Continue Analyzing the page and more.

Continue with Google

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Upgrade to Pro
Mavefund
Dashboard
Enlivex Therapeutics Ltd logo
ENLV

Enlivex Therapeutics Ltd

MaveScore 20 Low model confidence
Last Price US$0.53 As of Jul 02, 2026
Market Cap US$1.7m Company size context
7D Performance -9.10% Past 7 days
1Y Performance -48.78% Past 12 months
Model Rating
Historical model output for research review

Fundamental data date

Dec 31, 2016

3474 days old

Market price date

Jul 02, 2026

4 days old

Coverage

14/16

2 missing model inputs

Data quality

Review

Partial or delayed snapshot

Transparent research score

Why the model scores this stock

MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

MaveScore 20 Low confidence

Stored data quality

Freshness and coverage checks

Stored company inputs are available, but some dates or model fields are older or incomplete.

14/16 Partial or delayed snapshot

Quality

Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.

15/35 Weak

Financial Strength

Financial strength rewards durable profitability, margins, and positive free cash flow.

0/25 Weak

Valuation Support

Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

5/15 Weak

Momentum

Momentum highlights research candidates with supportive 3-month and 6-month price regimes.

0/15 Weak

Shareholder Alignment

Shareholder alignment rewards less dilutive share behavior and enough size for liquid research coverage.

0/10 Weak

Positive model output

More live company inputs are needed before positive research signals can be surfaced.

Research risks to review

  • Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.
  • Financial strength rewards durable profitability, margins, and positive free cash flow.
  • Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting. Missing inputs right now include net margin, gross margin.

Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Ratio
Dashboard Funda..tals Deep..lue Prediction Screener Map

Enlivex Therapeutics Ltd Overview

Industry: Biotechnology

Sector: Healthcare

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.

Enlivex Therapeutics Ltd is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.

Score

Price History & Performance

Review Enlivex Therapeutics Ltd in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.

Recent News



News Image
There is no doubt that Enlivex Therapeutics Ltd (ENLV) ticks all the boxes.
6 minutes ago
News Image
Why Is Amentum Stock Rising Over 9% Premarket Today?
27 minutes ago
News Image
Can La Tim Metal Industries Limited Deliver Relative Outperformance to Sector - Healthcare Stock Analysis & Go Beyond the Headlines With Analyst Picks
3 hours ago

Enlivex Therapeutics Ltd Competitors

Enlivex Therapeutics Ltd operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.

Earnings Per Share

EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.

Continue the analysis

Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.

View plans
Ticker Image

Enlivex Therapeutics Ltd

US$0.53

US$1.7m

-9.10%

-48.78%